Trevena Reports First Quarter 2023 Results and Provides Business Update
May 15, 2023 07:00 ET
|
Trevena, Inc.
OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million...
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023
May 09, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Approval of OLINVYK in China
May 08, 2023 07:00 ET
|
Trevena, Inc.
Trevena’s partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangsu Nhwa Additional $15...
Trevena to Participate in Three Upcoming Conferences
May 03, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study
March 30, 2023 07:02 ET
|
Trevena, Inc.
OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on...
Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
March 30, 2023 07:00 ET
|
Trevena, Inc.
Company announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study TRV045, a novel S1P receptor...
Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
March 27, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders
March 07, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY
February 14, 2023 08:00 ET
|
Trevena, Inc.
OLINVYK demonstrated a reduced impact on respiratory depression compared to IV morphine, among elderly/overweight subjects Study consistent with prior results that suggest OLINVYK provides a...
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement
January 09, 2023 07:00 ET
|
Trevena, Inc.
New Phase 1 clinical study designed to build on nonclinical evidence of anti-inflammatory signaling and potential disease-modifying effect of TRV045 in the treatment of epilepsy and other CNS...